A股異動 | 蔚藍生物漲4.31% 非洲豬瘟疫苗正在申請臨牀試驗
格隆匯3月20日丨蔚藍生物(603739.SH)漲4.31%,報22.53元,總市值35億元。農業農村部畜牧獸醫局副局長魏宏陽19日表示,疫苗需要安全、有效、質量可控。對於非洲豬瘟疫苗樂見其成,但也不能急於求成。根據我們掌握的情況,不同的機構取得了積極的進展,農業農村部已經收到一些單位提出的非洲豬瘟疫苗的臨牀試驗申請,農業農村部正在指導完善臨牀試驗方案,不降低標準的同時提高效率。蔚藍生物一直從事酶製劑、微生態以及動物保健品的研發、生產和銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.